Related Experiment Video
Updated: Dec 3, 2025
12:19
Three-Dimensional 3D Tumor Spheroid Invasion Assay
Published on: May 1, 2015
58.9K
Dickkopf-3 in Human Malignant Tumours: A Clinical Viewpoint
Eun-Ju Lee1, Que Thanh Thanh Nguyen2, Mooyul Lee3
1Department of Obstetrics and Gynecology, Chung-Ang University School of Medicine, Seoul, Republic of Korea ejlee@cau.ac.kr.
Anticancer Research
|October 28, 2020
Summary
Dickkopf-3 (DKK3) is a protein linked to cancer progression and patient survival. Its expression levels and methylation status may serve as valuable biomarkers and therapeutic targets in human malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Dickkopf-3 (DKK3), also known as REIC, is a secreted glycoprotein.
- Aberrant DKK3 expression is observed in various human malignant tumors.
- DKK3's role in cancer is linked to its regulation of key cellular pathways.
Purpose of the Study:
- To review the aberrant expression of DKK3 in human malignancies.
- To explore the potential of DKK3 as a clinical biomarker.
- To investigate DKK3 as a therapeutic candidate for cancer treatment.
Main Methods:
- Review of existing literature on DKK3 expression and function in cancer.
- Analysis of correlations between DKK3 methylation, protein expression, and clinical prognostic factors.
- Examination of DKK3's molecular mechanisms in malignant cells.
Main Results:
- DKK3 expression is significantly correlated with patient survival and other clinical prognostic factors.
- In malignant cells, DKK3 induces apoptosis, inhibits invasion, and remodels tumor vasculature.
- DKK3 regulates beta-catenin and c-Jun N-terminal kinase pathways crucial for carcinogenesis.
Conclusions:
- DKK3 holds significant potential as a clinical biomarker for human malignancies.
- DKK3 represents a promising therapeutic candidate for various cancer types.
- Further research into DKK3's role could lead to novel cancer diagnostics and treatments.
